75 mg

DRUG10 trials

Sponsors

UZ Leuven, Universitair Medisch Centrum Groningen, Universitair Medisch Centrum Groningen, Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), Institut Bergonie, Hospices Civils De Lyon

Conditions

Adult patients with intermediate unfavorable risk prostate cancer as per NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines Prostate Cancer. Version 2.2021)Breast cancerCOVID-19Chronic fatigue syndrome associated with post-COVID syndromeDuchenne muscular dystrophy; Cardiomyopathy; TachycardiaHerpes ZosterMajor depressive disorder (MDD)Oligorecurrent hormone-sensitive prostate cancer patients

Phase 2

Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women

CompletedNCT00918749

Warner ChilcottPostmenopausal Osteoporosis

Start: 2009-05-31End: 2009-10-31Updated: 2015-06-29

DARIUS : A RANDOMIZED NON-COMPARATIVE PHASE II MULTICENTRIC TRIAL ON SHORT TERM DAROLUTAMIDE (ODM-201) CONCOMITANT TO RADIATION THERAPY FOR PATIENTS WITH INTERMEDIATE UNFAVORABLE RISK PROSTATE CANCER

Active, not recruitingCTIS2023-509494-23-00

Institut BergonieAdult patients with intermediate unfavorable risk prostate cancer as per NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines Prostate Cancer. Version 2.2021)

Start: 2023-02-20Target: 62Updated: 2025-10-03

Investigation of pregabalin therapy and complex rehabilitation in treating chronic fatigue associated with post-COVID syndrome

CompletedCTIS2024-516174-30-01

Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im Prof. Dr Hab. Med. Eleonory ReicherChronic fatigue syndrome associated with post-COVID syndrome

Start: 2023-03-08End: 2025-10-30Target: 132Updated: 2024-10-31

POP-ELA: A short-term preoperative, window-of-opportunity study, evaluating activity and safety of Elacestrant monotherapy as compared to Elacestrant + ovarian function suppression (LHRH agonist) in premenopausal patients with stage I-II ER+/HER2- breast cancer

RecruitingCTIS2024-520051-24-00

Institut Gustave RoussyBreast cancer

Start: 2025-09-30Target: 140Updated: 2025-08-18

Phase 3

Metastasis-directed therapy for oligorecurrent prostate cancer : A randomized phase III trial.

RecruitingCTIS2022-502373-42-00

UZ LeuvenOligorecurrent hormone-sensitive prostate cancer patients

Start: 2022-04-25Target: 873Updated: 2025-03-31

Prospective Randomized trial of Everolimus replacing MMF/MP Acid by the RECOVAC consortium to increase VACcine response in kidney transplant patients

CompletedCTIS2023-503894-39-00

Universitair Medisch Centrum Groningen, Universitair Medisch Centrum GroningenCOVID-19, Herpes Zoster, impaired immunity +1

Start: 2023-08-22End: 2024-02-27Target: 110Updated: 2023-10-10

Apa/Enza short study (Shortened 12 months duration of androgen receptor signalling agent in combination with androgen deprivation therapy in patients with low-volume metastatic castration-sensitive prostate cancer: a randomized nationwide trial

RecruitingCTIS2023-506698-36-00

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)low-volume metastatic castration-sensitive prostate cancer

Start: 2024-02-02Target: 400Updated: 2025-12-03

The efficacy and safety of Metoprolol as add-on treatment to standard of care in preventing cardiomyopathy in patients with Duchenne Muscular Dystrophy aged 8-17 years. A randomized, double-blind, placebo controlled study

CompletedCTIS2024-515057-19-00

Medical University Of GdanskDuchenne muscular dystrophy; Cardiomyopathy; Tachycardia

Start: 2021-07-12End: 2025-10-06Target: 144Updated: 2024-12-16

Phase 4

Efficiency of everolimus for the treatment of kidney transplanted patients presenting a missing self-induced NK-mediated rejection (STARR)

RecruitingCTIS2024-513814-37-00

Hospices Civils De LyonRenal Transplantation

Start: 2020-12-03Target: 20Updated: 2024-09-30

Effectiveness of Trazodone on Emotional Blunting in Patients with Major Depressive: a Phase IV, Open-label, clinical study

Not yet recruitingCTIS2025-523267-38-00

Angelini Pharma Italia Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. Enunciabile Anche Angelini Pharma Italia S.p.A. Angelini Pharma S.p.A. A.C.R.A.F. S.p.A. Acraf S.p.A. Angelini S.p.A. aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.Major depressive disorder (MDD)

Target: 80Updated: 2026-07-30